Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study by Delal Akdeniz, Mark van Barele, Bernadette A.M. Heemskerk-Gerritsen, Ewout W. Steyerberg, Michael Hauptmann, Irma van de Beek, Klaartje van Engelen, Marijke R. Wevers, Encarnacion B. Gómez García, Margreet G.E.M. Ausems, Lieke P.V. Berger, Christi J. van Asperen, Muriel A. Adank, Margriet J. Collée, Denise J. Stommel-Jenner, Agnes Jager, Marjanka K. Schmidt, Maartje J. Hooning

“…We estimated cumulative CBC incidence using competing risks analysis. Hazard ratios (HR) for the effect of neo-adjuvant or adjuvant chemotherapy and different chemotherapeutic agents on CBC risk were estimated using Cox regression. …”
Get full text

Clinical Features of High-Grade Extremity and Trunk Sarcomas in Patients Aged 80 Years and Older: Why Are Outcomes Inferior? by Jungo Imanishi, Jungo Imanishi, Jungo Imanishi, Lester W. M. Chan, Lester W. M. Chan, Matthew L. Broadhead, Grant Pang, Grant Pang, Samuel Y. Ngan, Samuel Y. Ngan, John Slavin, Stephen Sharp, Peter F. M. Choong, Peter F. M. Choong, Peter F. M. Choong

“…Cox analysis revealed “age ≥80 years” as an independent risk factor for local failure and disease-specific mortality, with hazard ratios of 2.41 (95% CI: 1.09–5.32) and 2.52 (1.33–4.13), respectively. A competing risks analysis also showed that “age ≥80 years” was significantly associated with the disease-specific mortality.Conclusions: Oncological outcomes were significantly worse in high-grade sarcoma patients aged ≥80 years. …”
Get full text

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data by Heneghan, C, Onakpoya, I, Jones, M, Doshi, P, Del Mar, C, Hama, R, Thompson, M, Spencer, E, Mahtani, K, Nunan, D, Howick, J, Jefferson, T

“…After adjusting for time-dependent bias and potential confounding variables, competing risks analysis of the IPD showed insufficient evidence that oseltamivir reduced the risk of mortality (hazard ratio 1.03, 95% CI 0.64 to 1.65).Oseltamivir and zanamivir cause small reductions in the time to first alleviation of influenza symptoms in adults. …”

Endarterectomía coronaria y cirugía de revascularización by Daniel Pérez-Camargo, Mónica García-Bouza, Bunty Ramchandani, Javier Cobiella-Carnicer, Enrique Villagrán-Medinilla, Manuel Carnero-Alcazar, Luis C. Maroto-Castellanos

“…We compared long term survival in the total cohort and performed a proportional hazard risks analysis for survival. Also, we compared adverse cardiovascular events in a propensity score matched cohort. …”
Get full text

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. by Heneghan, C, Onakpoya, I, Jones, M, Doshi, P, Del Mar, C, Hama, R, Thompson, M, Spencer, E, Mahtani, K, Nunan, D, Howick, J, Jefferson, T

“…After adjusting for time-dependent bias and potential confounding variables, competing risks analysis of the IPD showed insufficient evidence that oseltamivir reduced the risk of mortality (hazard ratio 1.03, 95% CI 0.64 to 1.65).…”

Third‐generation continuous‐flow left ventricular assist devices: a comparative outcome analysis by device type by Maks Mihalj, Paul Philipp Heinisch, Patrick Schober, Monika Wieser, Michele Martinelli, Theo M.M.H. deBy, Joerg C. Schefold, Markus M. Luedi, Alexander Kadner, Thierry Carrel, Paul Mohacsi, Lukas Hunziker, David Reineke

“…The analysis included competing risks analysis and recurrent event regression analysis, with adjustment for confounders age, gender, body mass index (BMI), and Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) level. …”
Get full text